PCI Pharma expands its serialization capability
The multi-site installations support a variety of drug delivery forms, including bottles, unit cartons and parenteral kits, as well as unit dose wallets and child resistant/compliance prompting packaging.
PCI Pharma Services has announced a significant expansion of its serialization capability across the company's global supply network to support clients in advance of meeting both US DSCSA and EU FMD implementation dates.
The company has been actively serializing commercial products for both domestic and international markets for the past 5 years, with products destined for North America and Europe, in addition to emerging market geographies such as South Korea, Turkey, Brazil, China and others. In total, PCI supports medicines destined to over 100 global countries. The company's expansion triples its global serialization capacity in advance of upcoming DSCSA and FMD requirements.
PCI has partnered with Antares Vision, Marchesini and Domino for this latest installation, utilizing Antares’ leading serialization platform and technology architecture across a variety of serialization technology platforms and applications. The multi-site installations support a variety of drug delivery forms, including bottles, unit cartons and parenteral kits, as well as unit dose wallets and child resistant/compliance prompting packaging.
In addition, serialization technologies support ancillary and tertiary packaging, corrugated shippers and palletization solutions for supporting multi-level product aggregation. Aggregation is technically not a requirement for compliance to the 2017 DSCSA deadline, however PCI has strongly supported the advanced use of aggregation to realize significant benefits in packaging operations as well as the broader pharmaceutical supply chain.
Commenting on the expansion, Vice President of Global Engineering, Ken Richardson shared: “Serialization preparedness is the topic on everyone’s mind in the pharmaceutical industry. We are very excited about the next phase of our global serialization initiative and brand security program here at PCI. Having active developed and supported serialization over the past 5 years with numerous commercial applications around the world, we have a significant body of knowledge to share with clients. With these key learnings from practical applications of Serialization and anti-counterfeiting technologies, we have positioned ourselves to support our clients as they start to truly develop their own global Serialization strategies.
“This latest investment is considerable, and features what we believe are truly industry-leading technologies. The spotlight is on the industry to meet the November deadline and PCI has directed an amazing amount of financial resource, technological expertise and manpower to help our clients be prepared.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.